vs
西蒙地产集团（ELS）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是西蒙地产集团的1.9倍（$772.1M vs $397.6M），Revvity同比增速更快（5.9% vs 2.7%），过去两年Revvity的营收复合增速更高（9.0% vs 2.3%）
西蒙地产集团是美国头部房地产投资信托企业，投资范围涵盖购物中心、奥特莱斯及社区生活中心等商业地产业态，是美国规模最大的购物中心持有方，总部位于印第安纳州印第安纳波利斯，截至2024年12月末共持有232处物业权益。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ELS vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$397.6M
营收增速更快
RVTY
高出3.2%
2.7%
两年增速更快
RVTY
近两年复合增速
2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $397.6M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | 2.7% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.56 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELSRVTY
| Q1 26 | $397.6M | — | ||
| Q4 25 | $373.9M | $772.1M | ||
| Q3 25 | $393.3M | $698.9M | ||
| Q2 25 | $376.9M | $720.3M | ||
| Q1 25 | $387.3M | $664.8M | ||
| Q4 24 | $372.3M | $729.4M | ||
| Q3 24 | $387.3M | $684.0M | ||
| Q2 24 | $380.0M | $691.7M |
净利润ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $103.8M | $98.4M | ||
| Q3 25 | $100.4M | $46.7M | ||
| Q2 25 | $83.5M | $53.9M | ||
| Q1 25 | $114.4M | $42.2M | ||
| Q4 24 | $100.6M | $94.6M | ||
| Q3 24 | $86.9M | $94.4M | ||
| Q2 24 | $82.1M | $55.4M |
毛利率ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% |
营业利润率ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 26.5% | 14.5% | ||
| Q3 25 | 25.1% | 11.7% | ||
| Q2 25 | 22.3% | 12.6% | ||
| Q1 25 | 28.3% | 10.9% | ||
| Q4 24 | 27.2% | 16.3% | ||
| Q3 24 | 21.4% | 14.3% | ||
| Q2 24 | 21.5% | 12.4% |
净利率ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 27.8% | 12.7% | ||
| Q3 25 | 25.5% | 6.7% | ||
| Q2 25 | 22.2% | 7.5% | ||
| Q1 25 | 29.5% | 6.4% | ||
| Q4 24 | 27.0% | 13.0% | ||
| Q3 24 | 22.4% | 13.8% | ||
| Q2 24 | 21.6% | 8.0% |
每股收益（稀释后）ELSRVTY
| Q1 26 | $0.56 | — | ||
| Q4 25 | $0.52 | $0.86 | ||
| Q3 25 | $0.50 | $0.40 | ||
| Q2 25 | $0.42 | $0.46 | ||
| Q1 25 | $0.57 | $0.35 | ||
| Q4 24 | $0.51 | $0.77 | ||
| Q3 24 | $0.44 | $0.77 | ||
| Q2 24 | $0.42 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.8B | $7.3B |
| 总资产 | $5.7M | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B |
总债务ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.2B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ELSRVTY
| Q1 26 | $1.8B | — | ||
| Q4 25 | $1.8B | $7.3B | ||
| Q3 25 | $1.8B | $7.4B | ||
| Q2 25 | $1.7B | $7.6B | ||
| Q1 25 | $1.7B | $7.6B | ||
| Q4 24 | $1.7B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.4B | $7.9B |
总资产ELSRVTY
| Q1 26 | $5.7M | — | ||
| Q4 25 | $5.7B | $12.2B | ||
| Q3 25 | $5.7B | $12.1B | ||
| Q2 25 | $5.7B | $12.4B | ||
| Q1 25 | $5.6B | $12.4B | ||
| Q4 24 | $5.6B | $12.4B | ||
| Q3 24 | $5.6B | $12.8B | ||
| Q2 24 | $5.6B | $13.4B |
负债/权益比ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 1.91× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $571.1M | $182.0M | ||
| Q3 25 | $147.0M | $138.5M | ||
| Q2 25 | $131.3M | $134.3M | ||
| Q1 25 | $193.4M | $128.2M | ||
| Q4 24 | $596.7M | $174.2M | ||
| Q3 24 | $149.5M | $147.9M | ||
| Q2 24 | $143.1M | $158.6M |
自由现金流ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | $334.1M | $161.8M | ||
| Q3 25 | $75.7M | $120.0M | ||
| Q2 25 | $71.8M | $115.5M | ||
| Q1 25 | $148.2M | $112.2M | ||
| Q4 24 | $355.4M | $149.8M | ||
| Q3 24 | $91.1M | $125.6M | ||
| Q2 24 | $80.6M | $136.6M |
自由现金流率ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 89.4% | 21.0% | ||
| Q3 25 | 19.3% | 17.2% | ||
| Q2 25 | 19.1% | 16.0% | ||
| Q1 25 | 38.3% | 16.9% | ||
| Q4 24 | 95.5% | 20.5% | ||
| Q3 24 | 23.5% | 18.4% | ||
| Q2 24 | 21.2% | 19.7% |
资本支出强度ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 63.4% | 2.6% | ||
| Q3 25 | 18.1% | 2.6% | ||
| Q2 25 | 15.8% | 2.6% | ||
| Q1 25 | 11.7% | 2.4% | ||
| Q4 24 | 64.8% | 3.4% | ||
| Q3 24 | 15.1% | 3.3% | ||
| Q2 24 | 16.5% | 3.2% |
现金转化率ELSRVTY
| Q1 26 | — | — | ||
| Q4 25 | 5.50× | 1.85× | ||
| Q3 25 | 1.46× | 2.97× | ||
| Q2 25 | 1.57× | 2.49× | ||
| Q1 25 | 1.69× | 3.03× | ||
| Q4 24 | 5.93× | 1.84× | ||
| Q3 24 | 1.72× | 1.57× | ||
| Q2 24 | 1.74× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELS
| Rental income | $339.0M | 85% |
| Other | $37.2M | 9% |
| Annual membership subscriptions | $18.3M | 5% |
| Membership upgrade revenue | $3.1M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
